Table 1

Baseline characteristics of patients with mild-moderate Alzheimer's disease who were treated with donepezil for 6 months, by ADAS-Cog response group

All patients

ADAS-Cog

ADAS-Cog

ADAS-Cog

(n = 95)

improved

no change

worsened

(n = 19)

(n = 53)

(n = 23)


Baseline characteristics

Females, n (%)

68 (72)

15 (79)

36 (68)

17 (74)

Age, mean years (sd)

75.8 (7.7)

79.8 (8.2)

75.5 (6.3)

73.3 (8.9)

Education, mean years (sd)

11.1 (3.2)

10.5 (3.2)

11.0 (3.2)

11.6 (3.2)

Duration of illness, mean years (sd)

1.3 (1.5)

1.0 (1.0)

1.3 (1.7)

1.5 (1.6)

CDR = mild, n (%)

73 (77)

14 (74)

44 (83)

15 (65)

Baseline outcomes

CIBIS+, mean (sd)

3.7 (0.8)

3.7 (0.8)

3.6 (0.7)

3.9 (0.7)

MMSE, mean (sd)

19.9 (5.3)

20.0 (4.7)

20.6 (5.3)

18.3 (5.4)

ADAS-Cog, mean (sd)

24.6 (9.9)

26.4 (10.6)

23.2 (9.3)

26.3 (10.4)

PSMS, mean (sd)

8.8 (2.5)

9.3 (2.1)

8.8 (2.7)

8.3 (2.2)

IADL, mean (sd)

19.9 (5.4)

20.5 (4.6)

20.1 (5.4)

18.9 (6.1)

CSD, mean (sd)

5.7 (5.4)

6.4 (5.5)

5.5 (5.1)

5.9 (6.2)

Treatment goals set at baseline

PGAS-total, mean (sd)

8.6 (3.3)

8.2 (2.7)

8.7 (3.3)

8.6 (3.8)

PGAS-cognition, mean (sd)1

1.2 (0.8)

1.1 (0.7)

1.2 (0.8)

1.2 (0.7)

CGAS-total, mean (sd)

3.4 (1.3)

3.1 (0.8)

3.5 (1.4)

3.3 (1.2)

CGAS-cognition, mean (sd)2

2.1 (1.8)

2.5 (2.3)

2.2 (1.7)

1.8 (1.4)


1 81/95 patients/caregivers set cognition goals: respectively 16/19, 45/53 and, 20/23

2 81/95 clinicians set cognition goals, respectively 17/19, 45/53 and 19/23

Rockwood et al. BMC Neurology 2007 7:26   doi:10.1186/1471-2377-7-26

Open Data